Skip to main content
S&P 5007,811.54+0.59%DOW51,654.95+0.83%NASDAQ27,366.17+0.64%BTC$82,516.00+0.84%ETH$2,488.45+0.36%GOLD$4,220.30+1.52%OIL$91.66+0.19%
Smart Investors Daily
SID Premium
MediWound Ltd. logo

NASDAQ · MDWD

MediWound Ltd.

Healthcare · Biotechnology

$12.54

Up+$0.12 (+0.97%)

Updated Oct 10, 2026, 2:15 PM

SID Score

2.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
209.54M
P/E ratio
-7.4
Dividend yield
0.00%
52-week range
$12.42 – $20.03
Volume
92.65K
Avg. volume
79.29K

Price performance · MDWD

MDWD price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 9, 2026

MDWD closed at $12.54 after 21 trading sessions, down 4.35% for the selected period.

Last close
$12.54
Period change
-4.35%
Period low
$12.42
Period high
$13.95
Daily close
View OHLC price history
MDWD OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 9, 2026$12.42$13.15$12.42$12.5492.65K
Oct 8, 2026$12.80$13.11$12.42$12.42104.44K
Oct 7, 2026$13.13$13.23$12.8067$12.8572.53K
Oct 6, 2026$13.51$13.53$13.10$13.1558.79K
Oct 5, 2026$13.48$13.63$13.30$13.5149.89K
Oct 2, 2026$13.68$13.78$13.43$13.5247.95K
Oct 1, 2026$13.6608$13.77$13.47$13.6081.54K
Sep 30, 2026$13.80$13.98$13.59$13.7783.89K
Sep 29, 2026$14.04$14.04$13.74$13.8030.25K
Sep 28, 2026$13.68$14.00$13.68$13.9356.61K
Sep 25, 2026$13.86$14.035$13.70$13.8472.57K
Sep 24, 2026$13.77$13.97$13.5037$13.8361.09K
Sep 23, 2026$13.80$13.80$13.33$13.6573.15K
Sep 22, 2026$13.38$13.99$13.38$13.9580.69K
Sep 21, 2026$13.49$13.49$13.00$13.3172.46K
Sep 18, 2026$13.42$13.49$13.30$13.4081.94K
Sep 17, 2026$13.35$13.41$13.115$13.3544.32K
Sep 16, 2026$13.58$13.58$13.12$13.2279.02K
Sep 15, 2026$13.74$13.74$13.19$13.4780.53K
Sep 14, 2026$13.17$14.00$13.17$13.88167.85K
Sep 11, 2026$13.81$13.81$12.95$13.1178.33K

Latest MDWD news

The latest Smart Investors Daily articles mentioning MDWD.

Stock researchCompany · Overview

MDWD research

Overview

Company profile and research snapshot.

Company profile

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$36.00
Implied upside
—
Analysts
—
MDWD recent ratings
DateFirmRatingTarget
Aug 14, 2026OppenheimerOutperform—
May 28, 2026OppenheimerOutperform—
May 28, 2026HC Wainwright & Co.Buy—
Nov 21, 2025HC Wainwright & Co.Buy—
May 22, 2025HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 22, 2026

MediWound Awarded Additional $3.3 Million from U.S. Department of War to Advance Room-Temperature-Stable Formulation of NexoBrid®

MediWound Awarded Additional $3.3 Million from U.S. Department of War to Advance Room-Temperature-Stable Formulation of NexoBrid® Award raises the total program budget to $21.8 million and supports development through Investigational New Drug (IND) submission for battlefield burn care YAVNE, Israel, September 22, 2026 — MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that the U.S. Department of War (DoW) has awarded the

Yahoo · Sep 14, 2026

Independent DSMB Recommends MediWound’s EscharEx® Phase III VALUE Study Continue Without Modification

Independent DSMB Recommends MediWound’s EscharEx® Phase III VALUE Study Continue Without Modification DSMB did not identify safety concerns in pre-specified review; interim assessment and enrollment completion remain on track for end of the first quarter of 2027 YAVNE, Israel, September 14, 2026 (GLOBE NEWSWIRE) — MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that the independent Data and Safety Monitoring Board (DSMB)

Yahoo · Sep 2, 2026

MediWound to Present at the H.C. Wainwright 28th Annual Global Investment Conference

MediWound to Present at the H.C. Wainwright 28th Annual Global Investment Conference YAVNE, Israel, September 2, 2026 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Ofer Gonen, Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference. The conference will take place September 14–16, 2026, at the Lotte New York Palace Hotel in New York City. The f

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By